Search

Displaying results 2311 - 2320 of 3889 in total
  1. Drug

    Maridebart Cafraglutide

    go.drugbank.com/drugs/DB19339
    Investigational

    Maridebart Cafraglutide is under investigation in clinical trial NCT05669599 (Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity

  2. Drug

    Phencyclidine

    go.drugbank.com/drugs/DB03575
    ExperimentalIllicit

    A hallucinogen formerly used as a veterinary anesthetic, and briefly as a general anesthetic for humans. Phencyclidine is similar to ketamine in structure and in many of its effects. Like ketamine, it can produce a dissociative state. It...

  3. Drug

    Juglans californica pollen

    go.drugbank.com/drugs/DB10397
    Approved

    Juglans californica pollen is the pollen of the Juglans californica plant. Juglans californica pollen is mainly used in allergenic testing.

    Mixtures: Treatment Set TS333001
  4. Drug

    Olopatadine

    go.drugbank.com/drugs/DB00768
    Approved

    [A1172] In comparison to other anti-allergenic ophthalmic medications, olopatadine displays a good comfort and tolerability profile since it does not cause perturbation of cell membranes.

  5. Drug

    Xylitol

    go.drugbank.com/drugs/DB11195
    ApprovedInvestigational

    The recommended dose of xylitol for dental caries prevention is 6–10 g/day, and most adults can tolerate 40 g/day without adverse events [A22081].

  6. Drug

    Rolapitant

    go.drugbank.com/drugs/DB09291
    ApprovedInvestigational

    Unlike other available NK-1 receptor antagonists, rolapitant is not an inhibitor of Cytochrome P450 enzyme CYP3A4 and has a long elimination half-life, allowing a single dose to prevent both acute and

  7. Drug

    PTI-801

    go.drugbank.com/drugs/DB05300
    Investigational

    It is a combination of oxycodone with ultralow-dose naltrexone, an opioid antagonist.

  8. Drug

    GX-19 Vaccine

    go.drugbank.com/drugs/DB15891
    Investigational

    As of June 2020, the vaccine candidate is undergoing Phase I and Phase IIa trials to determine dose levels for safety and efficacy[A219758,L16488].

  9. Drug

    Rifamycin

    go.drugbank.com/drugs/DB11753
    ApprovedInvestigationalWithdrawn

    [L4800] This drug was also sent for review to the EMA in 2015 by Dr. Falk Pharma Gmbh and it was granted a waiver for the tested conditions.[L4801] … All of the derivatives have slight different physicochemical properties when compared to the parent structure.

  10. Drug

    Fexinidazole

    go.drugbank.com/drugs/DB12265
    Approved

    [A237555, A237560] Fexinidazole received a positive opinion from the European Medicines Agency (EMA) in November 2018 and was approved by the FDA on July 16, 2021.